The pharmacokinetics and tolerability of selexipag in patients with mild, moderate, or severe liver impairment and in volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2016
Price : $35 *
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 07 Apr 2016 Pooled analysis of 2 trials, including this and another study (see CTP 700238628) were published in the British Journal of Clinical Pharmacology.
- 13 Nov 2013 New trial record